Company intelligence / Profile preview

deepull

Barcelona, Catalonia, Spaindeepull.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The UllCORE BSI Test received FDA Breakthrough Device Designation in December 2024. Preliminary results show high concordance with positive blood culture and detection of more than twice as many clinically relevant pathogens compared to blood culture[1][2][5].

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnosticsMultiplex PCR
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on deepull.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deepull.

Explore the full profile